{"entity":{"id":"tqb2868","kind":"drug","name":"TQB2868","aka":[],"tldr":"TQB2868 is a bispecific antibody from Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., in registered phase 2 trials for pancreatic ductal adenocarcinoma.","summary":"TQB2868 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., in pancreatic ductal adenocarcinoma. A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of TQB2868","url":"https://clinicaltrials.gov/search?intr=TQB2868"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06767813"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"TQB2868","modality":"Bispecific antibody","mechanism":"A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tqb2868/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"trial":[{"id":"nct06767813","kind":"trial","name":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","route":"/trials/nct06767813/"}]}}